Isis shares jump on promising spinal disorder treatment data

(Reuters) – Shares of Isis Pharmaceuticals reached a new high on Friday after the company said a mid-stage trial of its experimental treatment for a rare spinal disorder showed that it increased…

    

Leave a Reply

Your email address will not be published.